Stockscreener 앱 받기
29.10
10.19%
2.69
시간 외 거래:
29.06
-0.04
-0.14%
전일 마감가:
$26.41
열려 있는:
$26.93
하루 거래량:
3.82M
Relative Volume:
1.77
시가총액:
$3.66B
수익:
$415.62M
순이익/손실:
$-2.38M
주가수익비율:
-1,024.65
EPS:
-0.0284
순현금흐름:
$16.92M
1주 성능:
+18.82%
1개월 성능:
+23.78%
6개월 성능:
+18.39%
1년 성능:
+34.54%
1일 변동 폭
$26.93
$29.46
1주일 범위
$24.30
$29.46
52주 변동 폭
$19.30
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.10 | 3.66B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - GlobeNewswire Inc.
An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares - Investing.com
Arcutis Biotherapeutics director Welgus sells $114k in shares By Investing.com - Investing.com India
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - TIKR.com
Arcutis Biotherapeutics director Welgus sells $114k in shares - Investing.com
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale - Stock Titan
Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861 - Bitget
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 9,98 - GuruFocus
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - Investing.com
Arcutis (ARQT) officer lines up Rule 144 stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - manilatimes.net
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Barchart.com
ARQT Stock Price, Quote & News - Syfe
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Nigeria
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Canada
Arcutis director Terrie Curran sells $956k in shares - Investing.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - theglobeandmail.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - TradingView
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K - benzinga.com
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026 - Kalkine Media
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics (ARQT) Gains 1.39% as Shares Push Toward Key ResistanceSupport Level Bounce - Vinanet
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcutis Biotherapeutics Inc 주식 (ARQT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Larry Todd Edwards | Former Officer |
Sep 16 '26 |
Proposed Sale |
25.00 |
341,980 |
8,549,500 |
0 |
| Matsuda Masaru | See Remarks |
Sep 16 '26 |
Sale |
25.00 |
3,674 |
91,853 |
112,508 |
| Welgus Howard G. | Director |
Sep 15 '26 |
Sale |
24.18 |
4,730 |
114,371 |
35,841 |
| Howard Welgus | Director |
Sep 15 '26 |
Proposed Sale |
24.18 |
4,730 |
114,371 |
0 |
| Welgus Howard G. | Director |
Sep 15 '26 |
Option Exercise |
7.93 |
4,096 |
32,475 |
40,571 |
| Matsuda Masaru | See Remarks |
Sep 08 '26 |
Sale |
25.03 |
9,989 |
249,986 |
116,182 |
| Masaru Matsuda | Officer |
Sep 08 '26 |
Proposed Sale |
25.03 |
13,663 |
341,933 |
0 |
| Terrie Curran | Director |
Aug 27 '26 |
Proposed Sale |
25.03 |
38,200 |
956,125 |
0 |
| Curran Terrie | Director |
Aug 27 '26 |
Option Exercise |
8.30 |
38,200 |
317,180 |
50,578 |
| Curran Terrie | Director |
Aug 27 '26 |
Sale |
25.03 |
38,200 |
956,123 |
23,526 |
0.75%
1.41%
자본화:
|
볼륨(24시간):